+91-8668442535

Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs Type (Top 3 Countries, Chemotherapy Drugs, Pipeline Drugs) - Growth, Future Prospects And Competitive Analysis, 2017 - 2025

Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer characterized by the abnormal production of myeloid blasts in the bone marrow and peripheral blood. The rising incidence of AML, a higher number of unmet needs, the expected launch of ideal molecules, and technological advances are prime factors driving the growth of the AML therapeutics market globally.

The report titled "Acute Myeloid Leukemia (AML) Therapeutics Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall AML therapeutics market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on drug type (chemotherapy drugs and pipeline drugs) and different geographical regions.

Geographically, the global AML therapeutics market is studied for the following regional markets:

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • Germany
  • Rest of Europe

Asia-Pacific

  • China
  • Japan
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • rest of Latin America

Middle East and Africa

  • GCC
  • the remainder of MEA

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global AML therapeutics market. Pipeline analysis and global epidemiology data have been included in the report. Tools such as key player market positioning and appealing investment propositions provide readers with insights into the competitive landscape of the global AML therapeutics market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global AML therapeutics market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global AML therapeutics market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Based on the drug type, the global acute myeloid leukemia (AML) therapeutics market is segmented as follows:

Chemotherapy Drugs

  • Cytarabine
  • Anthracyclines
  • Daunorubicin
  • Idarubicin
  • Mitoxantrone
  • Etoposide
  • Other

Pipeline Drugs

Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow that is characterized by an overproduction of immature myeloblasts or leukemic blasts. The AML therapeutics market is expected to show significant market growth during the forecast period, primarily due to the growing prevalence of leukemia and the presence of ideal pipeline molecules.

Treatment of AML is typically divided into two phases: induction therapy and post-remission therapy. It is studied that, in the base year 2016, cytarabine was a major revenue-generating segment due to its effectiveness, and hence it is a primary component of chemotherapeutic regimens. It is estimated that newly approved drugs such as gemtuzumab ozogamicin, Vyxeos, and midostaurin will show significant market growth during the forecast period. It is believed that the presence of strong pipeline molecules such as Bosutinib, Vosaroxin, Omacetaxine mepesuccinate, Venetoclax, and Quizartinib would assist the AML therapeutics market growth during the forecast period of 2017–2025.

For the purpose of this study, the global acute myeloid leukemia (AML) therapeutics market is categorized into three segments:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Acute myeloid leukemia (AML) is a type of blood cancer characterized by the expansion of myeloid blasts in the bone marrow and peripheral blood. According to Globocan, theworldwide prevalence of AML is approximately 1.5% and 1.4% for males and females, respectively. It is observed that currently, North America is dominating the AML therapeutics market due to its developed healthcare infrastructure, advanced technologies, the higher number of targeted populations, surge in funding by government agencies, and regulatory approval of newer molecules.

Furthermore, an increase in the incidence of AML and the upcoming regulatory approval of newer molecules would boost the AML therapeutics market during the forecast period. The American Cancer Society recorded approximately 21,380 new cases and 10,590 deaths from AML in the United States in 2017. It is estimated that Asia Pacific will show significant AML therapeutics market growth during the forecast period due to developing healthcare infrastructure, an increasing incidence of AML, and rising treatment awareness.

Frequently Asked Question:

The market for Acute Myeloid Leukemia Therapeutics Market is expected to reach USD$ 1,025.9 Mn in 2025.

The Acute Myeloid Leukemia Therapeutics Market is expected to see significant CAGR growth over the coming years, at 10.9%.

The report is forecasted from 2017 -2025.

The base year of this report is 2016.

bbott Laboratories,Astex Pharmaceuticals (A subsidiary of Otsuka Pharmaceutical),Boehringer Ingelheim GmbH,Bristol Myers Squibb,Celegene Corporation. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Sep 2017
Category:  Pharmaceuticals
Report ID:   58717
Report Format:   PDF
Pages:   120
Rating:    4.8 (80)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support